Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

Details on agency responses to committee recommendations can be found under the Performance Measures section for each committee in the fields “Agency Feedback” and “Agency Feedback Comment.”


HHS - 848 - National Institute on Drug Abuse Initial Review Group - Authorized by Law
Hide Section - GENERAL INFORMATION

GENERAL INFORMATION

Committee NameNational Institute on Drug Abuse Initial Review GroupAgency NameDepartment of Health and Human Services
Fiscal Year2022Committee Number848
Original Establishment Date10/27/1986Committee StatusChartered
Actual Termination Date Committee URL 
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*Unlimited
Current Charter Date8/7/1995Designated Fed Officer Position Title*Chief, Scientific Review Branch
Date Of Renewal Charter Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*Dharmendar
Exempt From Renewal*YesDesignated Federal Officer Middle Name
Specific Termination AuthorityDesignated Federal Officer Last Name*Rathore
Establishment Authority*Authorized by LawDesignated Federal Officer SuffixPh.D.
Specific Establishment Authority*42 U.S.C. 282(b)(16)Designated Federal Officer Phone*(301) 402-6965
Effective Date Of Authority*11/20/1985Designated Federal Officer Fax*
Exempt From EO 13875 Discretionary CmteNot ApplicableDesignated Federal Officer Email*dharmendar.rathore@nih.gov
Committee Type*Continuing
Presidential*No
Committee Function*Grant Review Committee
Hide Section - RECOMMENDATION/JUSTIFICATIONS

RECOMMENDATION/JUSTIFICATIONS

Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*This committee is composed of recognized biomedical and/or behavioral research authorities who represent the forefront of research and technical knowledge and who provide first-level merit review of highly scientific and technical research grant applications in the field relevant to drug abuse in the areas of biomedical, basic and clinical neuroscience, basic behavioral science, diagnostics, therapeutics, treatment, health services, epidemiology, prevention, human development, and AIDS. The committee reviewed 22 grants requesting $173,828,513.00.
How is membership balanced?*The members of this committee are authorities knowledgeable in the fields of biomedical, basic and clinical neuroscience, basic behavioral science, diagnostics, therapeutics, treatment, health services, epidemiology, prevention, human development, and AIDS.
How frequent & relevant are cmte mtgs?*The committee held three meetings during this reporting period. These meetings supported the mission and responsibility of the Institute.
Why advice can't be obtained elsewhere?*This committee is composed of recognized biomedical and/or behavioral research authorities who represent the forefront of research and technical knowledge and who provide first-level merit review of highly scientific and technical research grant applications and contract proposals. These evaluations and recommendations cannot be obtained from other sources because the specialized, complex nature of the applications and proposals requires a unique balance and breadth of expertise not available on the NIH staff or from other established sources.
Why close or partially close meetings?The meetings of the committee will be closed to the public for the review of grant applications. Sections 552b(c)(4) and 552b(c)(6) of the Government in the Sunshine Act permit the closing of meetings where discussion could reveal confidential trade secrets or commercial property such as patentable material and personal information, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Recommendation RemarksReports: This committee did not produce any reports during this reporting period.

Website: This committee does not have a dedicated website.

The DFO and Committee Decision Maker positions are held by the same individual based on assigned duties within the IC.
Hide Section - PERFORMANCE MEASURES

PERFORMANCE MEASURES

Outcome Improvement To Health Or Safety*NoAction Reorganize Priorities*No
Outcome Trust In GovernmentNoAction Reallocate ResourcesNo
Outcome Major Policy ChangesNoAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingYesAction Approved Grants Or Other PaymentsYes
Outcome Improved Service DeliveryNoAction OtherNo
Outcome Increased Customer SatisfactionNoAction CommentAn action of approved or recommended for grants receiving initial peer review by this committee does not infer that the grant will be or has been funded. Research grant applications submitted to NIH must go through a two-step review process that includes the initial peer review for scientific and technical merit and a second step of review and approval by a National Advisory Council for program relevance. In addition, prior to an award or funding being made, NIH staff must conduct an administrative review for a number of other considerations. These include alignment with NIH's funding principles, review of the project budget, assessment of the applicant's management systems, determination of applicant eligibility, and compliance with public policy requirements. After all these steps have been completed, NIH officials make funding decisions on individual grant applications.
Outcome Implement Laws/Reg RequirementsNoGrants Review*Yes
Outcome OtherNoNumber Of Grants Reviewed22
Outcome CommentN/ANumber Of Grants Recommended22
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$173,828,513.00
Cost Savings CommentNIH supported basic and clinical research accomplishments often take many years to unfold into new diagnostic tests and new ways to treat and prevent diseases.Grants Review CommentGrant Review
Number Of Recommendations*4,103Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentThis committee did not meet during the fiscal year.Access Agency WebsiteYes
% of Recs Fully Implemented*0.00%Access Committee WebsiteNo
% of Recs Fully Implemented CommentInformation on the research funded by NIH is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*0.00%Access PublicationsNo
% of Recs Partially Implemented CommentInformation on the research funded by NIH is available through the RePORT (Research Portfolio Online Reporting Tool) website. RePORT provides access to reports, data, and analyses of NIH research activities that advance the mission of the NIH, including information on NIH expenditures, strategic plans, reports on NIH funding, and reports on the organization and people involved in NIH research and research training. The RePORT website is located at http://report.nih.gov.Access OtherNo
Agency Feedback*YesAccess CommentN/A
Agency Feedback Comment*Information resulting from closed initial peer review meetings is subject to the Freedom of Information Act. The public can view information on research projects funded by NIH on the RePORT (Research Portfolio Online Reporting Tool) website located at http://report.nih.gov.Narrative Description*The goal of NIH research is to acquire new knowledge to help prevent, detect, diagnose, and treat disease and disability, from the rarest genetic disorder to the common cold. The NIH mission is to uncover new knowledge that will lead to better health for everyone. NIH works toward that mission by supporting the research of non-Federal scientists in universities, medical schools, hospitals, and research institutions throughout the country and abroad. Section 492 of the PHS Act states that The Secretary ...shall by regulation require appropriate technical and scientific peer review of - (A) applications...; and (B) biomedical and behavioral research and development contracts.
Hide Section - COSTS

COSTS

Payments to Non-Federal Members*$7,400.00Est Payments to Non-Fed Members Next FY*$17,400.00
Payments to Federal Members*$0.00Est. Payments to Fed Members Next FY*$0.00
Payments to Federal Staff*$126,841.00Estimated Payments to Federal Staff*$223,762.00
Payments to Consultants*$0.00Est. Payments to Consultants Next FY*$0.00
Travel Reimb. For Non-Federal Members*$0.00Est Travel Reimb Non-Fed Members nextFY*$33,480.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$0.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$0.00Est Travel Reimb to Consultants Next FY*$0.00
Other Costs$0.00Est. Other Costs Next FY*$4,816.00
Total Costs$134,241.00Est. Total Next FY*$279,458.00
Date Cost Last Modified9/15/2022 6:45 PMEst. Fed Staff Support Next FY*1.30
Federal Staff Support (FTE)*0.70Est Cost RemarksProjected costs for FY23 were increased in the event that in-person/hybrid meetings resume. In addition, an additional IRG will start meeting in FY23, as such the anticipated number of meetings, operating costs, federal staff cost, total staff support years have increased.
Cost RemarksMeetings were held virtually in FY22 due to the ongoing COVID-19 pandemic as such the FY22 Operating Costs are lower than what was projected on the FY21 FOP.  
Hide Section - Interest Areas

Interest Areas

Category
Area
Health
Health Care
Medicine
Health and Health Research
Hide Section - MEMBERS,MEETINGS AND ADVISORY REPORTS

MEMBERS,MEETINGS AND ADVISORY REPORTS

To View all the members, meetings and advisory reports for this committee please click here
Hide Section - CHARTERS AND RELATED DOCS

CHARTERS AND RELATED DOCS

No Documents Found
Hide Section - DATA FROM PREVIOUS YEARS

DATA FROM PREVIOUS YEARS

Committee

Data from Previous Years

 
ActionCommittee System IDCommittee NameFiscal Year
 COM-040495National Institute on Drug Abuse Initial Review Group2021
 COM-038770National Institute on Drug Abuse Initial Review Group2020
 COM-036653National Institute on Drug Abuse Initial Review Group2019
 COM-034868National Institute on Drug Abuse Initial Review Group2018
 COM-001666National Institute on Drug Abuse Initial Review Group2017
 COM-002662National Institute on Drug Abuse Initial Review Group2016
 COM-004116National Institute on Drug Abuse Initial Review Group2015
 COM-004409National Institute on Drug Abuse Initial Review Group2014
 COM-005913National Institute on Drug Abuse Initial Review Group2013
 COM-006508National Institute on Drug Abuse Initial Review Group2012
 COM-008163National Institute on Drug Abuse Initial Review Group2011
 COM-008672National Institute on Drug Abuse Initial Review Group2010
 COM-010356National Institute on Drug Abuse Initial Review Group2009
 COM-010743National Institute on Drug Abuse Initial Review Group2008
 COM-011875National Institute on Drug Abuse Initial Review Group2007
 COM-012859National Institute on Drug Abuse Initial Review Group2006
 COM-013981National Institute on Drug Abuse Initial Review Group2005
 COM-014544National Institute on Drug Abuse Initial Review Group2004
 COM-015857National Institute on Drug Abuse Initial Review Group2003
 COM-016775National Institute on Drug Abuse Initial Review Group2002
 COM-017589National Institute on Drug Abuse Initial Review Group2001
 COM-018452National Institute on Drug Abuse Initial Review Group2000
 COM-019545National Institute on Drug Abuse Initial Review Group1999
 COM-020299National Institute on Drug Abuse Initial Review Group1998
 COM-021415National Institute on Drug Abuse Initial Review Group1997